Edison Investment Research - Basilea Pharmaceutica AG (BSLN) Basilea Pharmaceutica - Final oncology asset (lisavanbulin) divested

Report

Edison Investment Research

Sean Conroy

Basilea Pharmaceutica - Final oncology asset (lisavanbulin) divested

Basilea Pharmaceutica has announced an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553), the remaining drug candidate from its oncology portfolio. Basilea’s other oncology assets were offloaded in 2022 (for initial consideration of CHF15m) following the company’s decision to right-size and focus exclusively on its anti-infectives franchise. Lisavanbulin is a tumour checkpoint controller and was being evaluated as a treatment for glioblastoma before Basilea decided to cease development following the strategic pivot. The initial purchase price is undisclosed, although Basilea will be eligible for a fixed double-digit share of any subsequent commercial partnerships.

21/06/2024 1 EN

Underlying

Basilea Pharmaceutica AG

Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.

See profile

CH0011432447 Six Swiss Exchange Switzerland

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Bryan Garnier

Basilea further streamlining operations

Basilea Pharmaceutica announced today that it has entered into an asset purchase agreement with the Glioblastoma Foundation Inc., for Basilea’s oncology drug candidate lisavanbulin (BAL101553), which has been developed as a potential therapy for glioblastoma. Basilea did not disclose the purchase p

June 20, 2024 June 20, 2024 1 EN

GlobeNewsWire

Basilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma Foundation

Basilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma Foundation Allschwil, 20. Juni 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass es eine Vereinbarung (Asset Purchase Agreement) zum Verkauf ihres onkologischen Wirkstoffkandidaten Lisavanbulin (BAL101553) an die Glioblastoma Foundation Inc. abgeschlossen hat. Lisavanbulin wurde als potenzielle Therapie für das G...

June 20, 2024 June 20, 2024 1 EN

Checkit - No intention to bid for Crimson Tide

On 26 June, Checkit announced that it did not intend to make a formal bid for Crimson Tide. Since Checkit’s original and revised all-equity proposals, another bidder, Ideagen, has expressed an intention to make an all-cash bid at a significantly higher price. Checkit will now refocus on organic growth and working towards profitability. Separately, an input VAT dispute with HMRC has concluded in Checkit’s favour, removing the related contingent liability.

2h / 23m 2h / 23m 1 EN

Toby Thorrington

Toby Thorrington

Severfield - Poised for expansion

The highlight of Severfield’s FY24 results was the 14% increase in underlying operating profit despite declining revenue. This gives a clue to the increasing quality of earnings as the company captures future projects and benefits from its internal digitalisation programme, Project Horizon. Furthermore, the Indian JV rapidly improved profit and is expanding capacity to meet growing demand. The balance sheet offers scope for both the £10m share buyback and potential M&A. Our forecasts are unchanged, and we introduce FY27 estimates. The 7.2x FY25e P/E is undemanding.

2h / 52m 2h / 52m 1 EN

Kate Heseltine

Kate Heseltine

Societe Anonyme des Bains de Mer - Sharing the love

Under comprehensive new management, Société des Bains de Mer (SBM) is building on its continued success (newly reported record EBITDA of c €150m for FY24) by looking to monetise its iconic Monte-Carlo brand in ‘new directions’ of international development and property. The purchase of a proposed luxury hotel in the French Alps (Courchevel), the company’s first such international transaction, and a new partnership with global restaurant group D.ream mark its intention to reach its customers where they travel and reside. While not immediately earnings transformative (the hotel faces long-term re...

4h / 7m 4h / 7m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Basilea Pharmaceutica - Final oncology asset (lisavanbulin) divested

Basilea further streamlining operations

Basilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma Foundation

Checkit - No intention to bid for Crimson Tide

Severfield - Poised for expansion

Societe Anonyme des Bains de Mer - Sharing the love

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe